Health Care [ 5/12 ] | Biotechnology [ 51/74 ]
NASDAQ | Common Stock
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.
Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy.
In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease.
The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate.
The company was founded in 2017 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 11, 26 | -0.25 Increased by +74.75% | -0.30 Increased by +16.67% |
| Mar 16, 26 | -0.27 Increased by +65.38% | -0.86 Increased by +68.60% |
| Nov 5, 25 | -0.33 Increased by +62.92% | -0.48 Increased by +31.25% |
| Aug 14, 25 | -0.68 Decreased by -6.25% | -0.66 Decreased by -3.03% |
| May 12, 25 | -0.99 Decreased by -28.57% | -0.77 Decreased by -28.57% |
| Mar 24, 25 | -0.78 Increased by +8.24% | -0.72 Decreased by -8.33% |
| Nov 13, 24 | -0.89 Increased by +25.83% | -0.67 Decreased by -32.84% |
| Aug 12, 24 | -0.64 | -0.69 Increased by +7.25% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 0.00 Decreased by N/A% | -20.20 M Increased by +38.16% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 25 | 0.00 Decreased by -100.00% | -20.92 M Increased by +19.31% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -20.28 M Increased by +31.22% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -26.10 M Decreased by -22.91% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -32.66 M Decreased by -50.61% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 1.94 M Increased by +N/A% | -25.92 M Decreased by -82.73% | Decreased by -1.33 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -29.49 M Decreased by -46.65% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -21.24 M Decreased by -58.01% | Decreased by N/A% Decreased by N/A% |